ES2894963T3 - Variantes de TNFSF15 y DcR3 asociadas con la enfermedad de Crohn - Google Patents

Variantes de TNFSF15 y DcR3 asociadas con la enfermedad de Crohn Download PDF

Info

Publication number
ES2894963T3
ES2894963T3 ES18201967T ES18201967T ES2894963T3 ES 2894963 T3 ES2894963 T3 ES 2894963T3 ES 18201967 T ES18201967 T ES 18201967T ES 18201967 T ES18201967 T ES 18201967T ES 2894963 T3 ES2894963 T3 ES 2894963T3
Authority
ES
Spain
Prior art keywords
seq
subject
variants
tnfsf15
crohn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES18201967T
Other languages
English (en)
Spanish (es)
Other versions
ES2894963T8 (es
Inventor
Dermot P Mcgovern
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cedars Sinai Medical Center
Original Assignee
Cedars Sinai Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cedars Sinai Medical Center filed Critical Cedars Sinai Medical Center
Application granted granted Critical
Publication of ES2894963T3 publication Critical patent/ES2894963T3/es
Publication of ES2894963T8 publication Critical patent/ES2894963T8/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ES18201967T 2013-05-17 2014-05-16 Variantes de TNFSF15 y DcR3 asociadas con la enfermedad de Crohn Active ES2894963T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361824932P 2013-05-17 2013-05-17

Publications (2)

Publication Number Publication Date
ES2894963T3 true ES2894963T3 (es) 2022-02-16
ES2894963T8 ES2894963T8 (es) 2022-02-24

Family

ID=51899024

Family Applications (1)

Application Number Title Priority Date Filing Date
ES18201967T Active ES2894963T3 (es) 2013-05-17 2014-05-16 Variantes de TNFSF15 y DcR3 asociadas con la enfermedad de Crohn

Country Status (7)

Country Link
US (4) US20160090629A1 (enExample)
EP (3) EP2997165A4 (enExample)
JP (5) JP6482533B2 (enExample)
KR (4) KR102295125B1 (enExample)
CN (1) CN105358713B (enExample)
ES (1) ES2894963T3 (enExample)
WO (1) WO2014186750A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010062960A2 (en) 2008-11-26 2010-06-03 Cedars-Sinai Medical Center METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNFα THERAPY IN INFLAMMATORY BOWEL DISEASE
MX2014003689A (es) 2011-09-30 2014-12-05 Teva Pharmaceuticals Australia Pty Ltd Anticuerpos contra tl1a y sus usos.
KR20230109779A (ko) 2013-03-27 2023-07-20 세다르스-신나이 메디칼 센터 Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한섬유증 및 염증의 완화 및 반전
CN105358713B (zh) 2013-05-17 2020-02-28 雪松-西奈医学中心 与克罗恩病相关的tnfsf15和dcr3的变体
EP4105236A1 (en) 2013-07-19 2022-12-21 Cedars-Sinai Medical Center Anti-tl1a (tnfsf15) antibody for treatment of inflammatory bowel disease
CA2994719A1 (en) 2015-08-21 2017-03-02 The Children's Hospital Of Philadelphia Methods of treating autoimmune conditions in patients with genetic variations in dcr3 or in a dcr3 network gene
TWI703158B (zh) 2015-09-18 2020-09-01 美商希佛隆公司 特異性結合tl1a之抗體
KR20180127416A (ko) 2016-03-17 2018-11-28 세다르스-신나이 메디칼 센터 Rnaset2를 통한 염증성 장 질환의 진단 방법
CN109476698B (zh) * 2016-05-20 2023-10-17 西达-赛奈医疗中心 基于基因的炎性肠病诊断
CN121371183A (zh) 2018-09-07 2026-01-23 费城儿童医院 用于淋巴系统病症的诊断和治疗的组合物和方法
CN114375339A (zh) 2019-05-14 2022-04-19 普罗米修斯生物科学公司 Tl1a患者选择方法、系统和装置
CN121949515A (zh) * 2019-09-13 2026-05-01 协和麒麟株式会社 DcR3变体
JP2023551602A (ja) * 2020-11-13 2023-12-08 プロメテウス バイオサイエンシーズ，インク． Ｔｌ１ａを標的とする炎症性疾患の治療のための方法、システム、およびキット
IL325993A (en) 2023-08-11 2026-03-01 Paragon Therapeutics Inc TL1A binding proteins and methods of use

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US20090186034A1 (en) * 2006-12-19 2009-07-23 Genetech, Inc. Gene expression markers for inflammatory bowel disease
US20100190162A1 (en) 2007-02-26 2010-07-29 Cedars-Sinai Medical Center Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease
WO2009052512A2 (en) 2007-10-19 2009-04-23 Cedars-Sinai Medical Center Methods of using genetic variants to diagnose and predict inflammatory bowel disease
HRP20150684T1 (hr) 2008-02-19 2015-09-11 The Children's Hospital Of Philadelphia, Abramson Pediatric Research Center, Office of Technology Transfer Identifikacija specifiäśnih mjesta nastanka - genetski loci - upalne bolesti crijeva kod djece i postupci njihove uporabe u takvoj dijagnozi te njihovo lijeäśenje
WO2010118210A1 (en) * 2009-04-08 2010-10-14 Cedars-Sinai Medical Center Methods of predicting complication and surgery in crohn's disease
NZ595471A (en) * 2009-04-14 2014-01-31 Nestec Sa Inflammatory bowel disease prognostics
JP5960707B2 (ja) 2010-10-18 2016-08-02 ネステク ソシエテ アノニム 抗薬物抗体アイソタイプを決定するための方法
ES2530175T3 (es) 2011-02-17 2015-02-26 Nestec S.A. Ensayos para la detección de autoanticuerpos contra fármacos anti-TNF
AU2012259312A1 (en) 2011-05-20 2013-12-12 Government Of The United States, As Represented By The Secretary Department Of Health And Human Services Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology and antibodies thereof
WO2012174338A2 (en) 2011-06-15 2012-12-20 Glaxosmithkline Llc Method of selecting therapeutic indications
EP2565277A1 (en) 2011-09-05 2013-03-06 Progenika Biopharma, S.A. Method for predicting radiographic severity in ankylosing spondylitis
EP2769321B1 (en) 2011-10-21 2016-06-01 Nestec S.A. Methods for improving inflammatory bowel disease diagnosis
CN105358713B (zh) 2013-05-17 2020-02-28 雪松-西奈医学中心 与克罗恩病相关的tnfsf15和dcr3的变体
CR20180365A (es) 2015-12-16 2018-09-28 Amgen Inc PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
KR20180127416A (ko) 2016-03-17 2018-11-28 세다르스-신나이 메디칼 센터 Rnaset2를 통한 염증성 장 질환의 진단 방법

Also Published As

Publication number Publication date
US20250243548A1 (en) 2025-07-31
JP2018148931A (ja) 2018-09-27
JP2022111329A (ja) 2022-07-29
JP2025023316A (ja) 2025-02-14
KR20210107176A (ko) 2021-08-31
US20180230543A1 (en) 2018-08-16
JP2020127437A (ja) 2020-08-27
JP2016526875A (ja) 2016-09-08
WO2014186750A3 (en) 2015-01-08
KR20160009582A (ko) 2016-01-26
KR102295125B1 (ko) 2021-08-31
US20160090629A1 (en) 2016-03-31
CN105358713A (zh) 2016-02-24
US12281359B2 (en) 2025-04-22
EP3498867A1 (en) 2019-06-19
EP3988673A2 (en) 2022-04-27
EP2997165A2 (en) 2016-03-23
US20210371931A1 (en) 2021-12-02
EP3498867B1 (en) 2021-09-29
EP2997165A4 (en) 2017-03-08
KR20230093538A (ko) 2023-06-27
JP6482533B2 (ja) 2019-03-13
WO2014186750A2 (en) 2014-11-20
ES2894963T8 (es) 2022-02-24
EP3988673A3 (en) 2022-08-03
KR20250130857A (ko) 2025-09-02
CN105358713B (zh) 2020-02-28

Similar Documents

Publication Publication Date Title
JP2022111329A (ja) クローン病に関連するｔｎｆｓｆ１５及びｄｃｒ３の変異体
Werbrouck et al. Acute normal tissue reactions in head-and-neck cancer patients treated with IMRT: influence of dose and association with genetic polymorphisms in DNA DSB repair genes
US20160096885A1 (en) Distinct effects of ifn-gamma and il-17 on tl1a modulated inflammation and fibrosis
Karayasheva et al. Association study for the role of matrix metalloproteinases 2 and 3 gene polymorphisms in dental caries susceptibility
Baatjes et al. CYP19A1 rs10046 pharmacogenetics in postmenopausal breast cancer patients treated with aromatase inhibitors: one-year follow-up
Lim et al. Epidermal growth factor gene polymorphism is different between schizophrenia and lung cancer patients in Korean population
Szczepańska et al. Involvement of vascular endothelial growth factor− 460 C/T,+ 405 G/C and+ 936 C/T polymorphisms in the development of endometriosis
Teixeira et al. SH3BP2-encoding exons involved in cherubism are not associated with central giant cell granuloma
HK40072596A (en) Variants of tnfsf15 and dcr3 associated with crohn's disease
CN102787163B (zh) 检测OTOF基因c.1671_1673delG突变的试剂盒
Kacerovska et al. Carney complex: a clinicopathologic and molecular biological study of a sporadic case, including extracutaneous and cutaneous lesions and a novel mutation of the PRKAR1A gene
CN106244727A (zh) 一种hpv‑16与宿主遗传因素的联合效应的测试方法
Guan et al. Risk of gastric ulcer contributed by genetic polymorphisms of PSCA: A case-control study based on Chinese Han population
Francis et al. Hypoxia responsiveness linked variant in EGLN1 gene is enriched in oral cancer patients
Hassan et al. Genetic polymorphism of interleukin-4 gene in inflammatory bowel disease of Iraqi patients
CN102732613A (zh) 检测OTOF基因c.5833delG突变的试剂盒
Bagheri et al. Association study of transforming growth factor alpha TaqI polymorphism and the risk of cleft lip and/or palate in an Iranian population
Omelchenko et al. POLYMORPHISMS IN THE GENES OF VASCULAR ENDOTHELIAL GROWTH FACTOR ARE ASSOCIATED WITH THE EARLIER ONSET OF RHEUMATOID ARTHRITIS
CN102732615A (zh) 检测OTOF基因c.2382_2383delC突变的试剂盒
Omran et al. Relationship between STK39 Genotype and Vitamin D3 in Hypertension
Lucky et al. (VDR) Gene Polymorphisms–Rapid and noninvasive oral detection Method
Izquierdo et al. 813 MOLECULAR CHARACTERIZATION OF UPPER URINARY TRACT TUMOURS
Ruchusatsawat Association of the interleukin-10 distal promoter (-2763A/C) polymorphism with late-onset psoriasis
Rouprêt et al. 812 GENETIC VARIABILITY WITHIN 8Q24 CONFERS ENHANCED RISK OF UROTHELIAL CELL CARCINOMA OF THE UPPER URINARY TRACT
Cornu et al. 814 IMPORTANCE OF ALLELIC INSTABILITY OF URINARY MICROSATELLITES MARKERS FOR CONSERVATIVE MANAGEMENT OF UPPER URINARY TRACT UROTHELIAL CELL CARCINOMA